Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

Virus Research

Volumn 170, Issue 1-2, 2012, Pages 1-14

  Belda, Oscar ^a   Targett Adams, Paul ^a  

^a MEDIVIR AB   (Sweden)

Author keywords

Combination therapy; Direct acting antiviral; Hepatitis C virus; Inhibitor; Mechanism of action; NS5A

Indexed keywords

ABT 267; ABT 333; ABT 450R; ACH 2928; ACH 3102; ANTIVIRUS AGENT; ASUNAPREVIR; BIOTIN; BMS 791325; BMS 986094; DACLATASVIR; DIRECT ACTING ANTIVIRAL; EDP 239; GS 5885; GS 9451; GSK 2336805; IDX 719; MK 8742; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PPI 461; PPI 668; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; BOVINE VIRAL DIARRHEA; CHEMICAL GENETICS; CYTOTOXICITY; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REPLICON; REVIEW; RNA REPLICATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR TARGETED THERAPY; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84870441080     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.09.007     Document Type: Review

References (125)

1. Alberti A., Chemello L., Benvegnu L. Natural history of hepatitis C. Journal of Hepatology 1999, 31(Suppl. 1):17-24.
2. Appel N., Pietschmann T., Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. Journal of Virology 2005, 79(5):3187-3194.
3. Appel N., Schaller T., Penin F., Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. The Journal of Biological Chemistry 2006, 281(15):9833-9836.
4. Appel N., Zayas M., Miller S., Krijnse-Locker J., Schaller T., Friebe P., Kallis S., Engel U., Bartenschlager R. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathogens 2008, 4(3):e1000035.
5. Asselah T., Vidaud D., Doloy A., Boyer N., Martinot M., Vidaud M., Valla D., Marcellin P. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003, 52(6):900-902.
6. Bartenschlager R., Cosset F.L., Lohmann V. Hepatitis C virus replication cycle. Journal of Hepatology 2010, 53(3):583-585.
7. Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends in Microbiology 2011, 19(2):95-103.
8. Bell T.W. Drugs for hepatitis C: unlocking a new mechanism of action. ChemMedChem 2010, 5(10):1663-1665.
9. Bischofberger, N.W., 2012. Gilead press release, July 26.
10. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290(5498):1972-1974.
11. Brass V., Bieck E., Montserret R., Wolk B., Hellings J.A., Blum H.E., Penin F., Moradpour D. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. The Journal of Biological Chemistry 2002, 277(10):8130-8139.
12. Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., Watanabe H., McPhee F., Hughes E., Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55(3):742-748.
13. Deuffic-Burban S., Poynard T., Sulkowski M.S., Wong J.B. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. Journal of Viral Hepatitis 2007, 14(2):107-115.
14. Dimitrova M., Imbert I., Kieny M.P., Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. Journal of Virology 2003, 77(9):5401-5414.
15. Egger D., Wolk B., Gosert R., Bianchi L., Blum H.E., Moradpour D., Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. Journal of Virology 2002, 76(12):5974-5984.
16. Elazar M., Cheong K.H., Liu P., Greenberg H.B., Rice C.M., Glenn J.S. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. Journal of Virology 2003, 77(10):6055-6061.
17. Evans M.J., Rice C.M., Goff S.P. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(35):13038-13043.
18. Falck-Ytter Y., Kale H., Mullen K.D., Sarbah S.A., Sorescu L., McCullough A.J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine 2002, 136(4):288-292.
19. Ferenci P., Reddy K.R. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antiviral Therapy 2011, 16(8):1187-1201.
20. Flint M., Mullen S., Deatly A.M., Chen W., Miller L.Z., Ralston R., Broom C., Emini E.A., Howe A.Y. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrobial Agents and Chemotherapy 2009, 53(2):401-411.
21. Foster T.L., Belyaeva T., Stonehouse N.J., Pearson A.R., Harris M. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. Journal of Virology 2010, 84(18):9267-9277.
22. Fridell R.A., Qiu D., Valera L., Wang C., Rose R.E., Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. Journal of Virology 2011, 85(14):7312-7320.
23. Fridell R.A., Qiu D., Wang C., Valera L., Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrobial Agents and Chemotherapy 2010, 54(9):3641-3650.
24. Fridell R.A., Wang C., Sun J.H., O'Boyle D.R., Nower P., Valera L., Qiu D., Roberts S., Huang X., Kienzle B., Bifano M., Nettles R.E., Gao M. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011, 54(6):1924-1935.
25. Gane E.J., Stedman C.A., Hyland R.H., Sorensen R.D., Symonds W.T., Hindes R.G., Berrey M.M. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. Journal of Hepatology 2012, 56:S438-S439.
26. Gao M. HCV NS5A targeted antivirals (BMS-790052). 5th International Workshop on Hepatitis C Resistance and New Compounds 2010, Archived at: http://www.natap.org/2010/HCVresist/HCVresist_07.htm.
27. Gao M., Nettles R.E., Belema M., Snyder L.B., Nguyen V.N., Fridell R.A., Serrano-Wu M.H., Langley D.R., Sun J.H., O'Boyle D.R., Lemm J.A., Wang C., Knipe J.O., Chien C., Colonno R.J., Grasela D.M., Meanwell N.A., Hamann L.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465(7294):96-100.
28. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444.
29. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
30. Giannini C., Giannelli F., Monti M., Careccia G., Marrocchi M.E., Laffi G., Gentilini P., Zignego A.L. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. The Journal of Laboratory and Clinical Medicine 1999, 134(1):68-73.
31. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. Journal of Virology 2003, 77(9):5487-5492.
32. Graham E.J., Hunt R., Shaw S.M., Pickford C., Hammond J., Westby M., Targett-Adams P. Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals. Journal of Virological Methods 2011, 174(1-2):153-157.
33. Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D., Jaeger J., Harris M.P., Rowlands D.J. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Letters 2003, 535(1-3):34-38.
34. Guedj J., Rong L., Dahari H., Perelson A.S. A perspective on modelling hepatitis C virus infection. Journal of Viral Hepatitis 2010, 17(12):825-833.
35. Hamamoto I., Nishimura Y., Okamoto T., Aizaki H., Liu M., Mori Y., Abe T., Suzuki T., Lai M.M., Miyamura T., Moriishi K., Matsuura Y. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. Journal of Virology 2005, 79(21):13473-13482.
36. Hanoulle X., Badillo A., Verdegem D., Penin F., Lippens G. The domain 2 of the HCV NS5A protein is intrinsically unstructured. Protein and Peptide Letters 2010, 17(8):1012-1018.
37. Hanoulle X., Verdegem D., Badillo A., Wieruszeski J.M., Penin F., Lippens G. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochemical and Biophysical Research Communications 2009, 381(4):634-638.
38. Huang L., Hwang J., Sharma S.D., Hargittai M.R., Chen Y., Arnold J.J., Raney K.D., Cameron C.E. Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. The Journal of Biological Chemistry 2005, 280(43):36417-36428.
39. Huang Y., Staschke K., De Francesco R., Tan S.L. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?. Virology 2007, 364(1):1-9.
40. Hughes M., Griffin S., Harris M. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. The Journal of General Virology 2009, 90(Pt 6):1329-1334.
41. Hugle T., Fehrmann F., Bieck E., Kohara M., Krausslich H.G., Rice C.M., Blum H.E., Moradpour D. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 2001, 284(1):70-81.
42. Hwang J., Huang L., Cordek D.G., Vaughan R., Reynolds S.L., Kihara G., Raney K.D., Kao C.C., Cameron C.E. Hepatitis C virus non-structural protein 5A (NS5A): Biochemical characterization of a novel structural class of RNA-binding proteins. Journal of Virology 2010.
43. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364(25):2405-2416.
44. Jones D.M., McLauchlan J. Hepatitis C virus: assembly and release of virus particles. The Journal of Biological Chemistry 2010, 285:22733-22739.
45. Jones L.H., Beal D., Selby M.D., Everson O., Burslem G.M., Dodd P., Millbank J., Tran T.D., Wakenhut F., Graham E.J., Targett-Adams P. In-cell click labelling of small molecules to determine subcellular localisation. Journal of Chemical Biology 2011, 4(2):49-53.
46. Kaneko T., Tanji Y., Satoh S., Hijikata M., Asabe S., Kimura K., Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochemical and Biophysical Research Communications 1994, 205(1):320-326.
47. Kanwal F., Hoang T., Spiegel B.M., Eisen S., Dominitz J.A., Gifford A., Goetz M., Asch S.M. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007, 46(6):1741-1749.
48. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nature reviews. Drug Discovery 2004, 3(8):711-715.
49. Lavanchy D. The global burden of hepatitis C. Liver International: Official Journal of the International Association for the Study of the Liver 2009, 29(Suppl. 1):74-81.
50. Lawitz E., Marbury T., Campbell A., Dumas E., Kapoor M., Pilot-Matias T., Krishnan P., Setze C., Xie W., Podsadecki T., Bernstein B., Williams L. Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT-1)-infected treatment-naive subjects. Journal of Hepatology 2012, 56:S469-S470.
51. Lawitz E.J., Gruener D., Hill J.M., Marbury T., Moorehead L., Mathias A., Cheng G., Link J.O., Wong K.A., Mo H., McHutchison J.G., Brainard D.M. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Journal of Hepatology 2012, 57:24-31.
52. Lee C., Ma H., Hang J.Q., Leveque V., Sklan E.H., Elazar M., Klumpp K., Glenn J.S. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 2011, 414(1):10-18.
53. Lemm J.A., Leet J.E., O'Boyle D.R., Romine J.L., Huang X.S., Schroeder D.R., Alberts J., Cantone J.L., Sun J.H., Nower P.T., Martin S.W., Serrano-Wu M.H., Meanwell N.A., Snyder L.B., Gao M. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrobial Agents and Chemotherapy 2011, 55(8):3795-3802.
54. Lemm J.A., O'Boyle D., Liu M., Nower P.T., Colonno R., Deshpande M.S., Snyder L.B., Martin S.W., St Laurent D.R., Serrano-Wu M.H., Romine J.L., Meanwell N.A., Gao M. Identification of hepatitis C virus NS5A inhibitors. Journal of Virology 2010, 84(1):482-491.
55. Liang Y., Ye H., Kang C.B., Yoon H.S. Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry 2007, 46(41):11550-11558.
56. Lim P.J., Chatterji U., Cordek D., Sharma S.D., Garcia-Rivera J.A., Cameron C.E., Lin K., Targett-Adams P., Gallay P.A. Correlation between NS5A dimerization and HCV replication. The Journal of Biological Chemistry 2012, 287(36):30861-30873.
57. Lin H.M., Wang J.C., Hu H.S., Wu P.S., Yang C.C., Wu C.P., Pu S.Y., Hsu T.A., Jiaang W.T., Chao Y.S., Chern J.H., Yeh T.K., Yueh A. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor. Antimicrobial Agents and Chemotherapy 2012, 56(1):44-53.
58. Lin K., Perni R.B., Kwong A.D., Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrobial Agents and Chemotherapy 2006, 50(5):1813-1822.
59. Lindenbach B.D., Pragai B.M., Montserret R., Beran R.K., Pyle A.M., Penin F., Rice C.M. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. Journal of Virology 2007, 81(17):8905-8918.
60. Liu R., Kong R., Mann P., Ingravallo P., Zhai Y., Xia E., Ludmerer S., Kozlowski J., Coburn C. In vitro resistance analysis of HCV NS5A inhibitor: MK-8742 demonstrates increased potency against clinical resistance variants and higher resistance barrier. Journal of Hepatology 2012, 56:S334-S335.
61. Lohmann V., Hoffmann S., Herian U., Penin F., Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. Journal of Virology 2003, 77(5):3007-3019.
62. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. Journal of Virology 2001, 75(3):1437-1449.
63. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424):110-113.
64. Lok A., Gardiner D., Hezode C., Lawitz E., Bourliere M., Everson G., Marcellin P., Rodriguez-Torres M., Pol S., Serfaty L., Eley T., Huang S.P., Wind-Rotolo M., McPhee F., Grasela D., Pasquinelli C. Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders. Journal of Hepatology 2012, 56:S557.
65. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., Reindollar R., Rustgi V., McPhee F., Wind-Rotolo M., Persson A., Zhu K., Dimitrova D.I., Eley T., Guo T., Grasela D.M., Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England Journal of Medicine 2012, 366(3):216-224.
66. Love R.A., Brodsky O., Hickey M.J., Wells P.A., Cronin C.N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. Journal of Virology 2009, 83(9):4395-4403.
67. Lundin M., Monne M., Widell A., Von Heijne G., Persson M.A. Topology of the membrane-associated hepatitis C virus protein NS4B. Journal of Virology 2003, 77(9):5428-5438.
68. Ly K.N., Xing J., Klevens R.M., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 2012, 156(4):271-278.
69. Magiorkinis G., Magiorkinis E., Paraskevis D., Ho S.Y., Shapiro B., Pybus O.G., Allain J.P., Hatzakis A. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Medicine 2009, 6(12):e1000198.
70. Manns M.P., Markova A.A., Serrano B.C., Cornberg M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32(Suppl. 1):27-31.
71. Masaki T., Suzuki R., Murakami K., Aizaki H., Ishii K., Murayama A., Date T., Matsuura Y., Miyamura T., Wakita T., Suzuki T. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. Journal of Virology 2008, 82(16):7964-7976.
72. Matsubara T., Sumazaki R., Shin K., Nagai Y., Takita H. Genotyping of hepatitis C virus: coinfection by multiple genotypes detected in children with chronic posttransfusion hepatitis C. Journal of Pediatric Gastroenterology and Nutrition 1996, 22(1):79-84.
73. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nature Cell Biology 2007, 9(9):1089-1097.
74. Monod J., Wyman J., Changeux J.P. On the nature of allosteric transitions: a plausible model. Journal of Molecular Biology 1965, 12:88-118.
75. Moradpour D., Brass V., Bieck E., Friebe P., Gosert R., Blum H.E., Bartenschlager R., Penin F., Lohmann V. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. Journal of Virology 2004, 78(23):13278-13284.
76. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nature reviews. Microbiology 2007, 5(6):453-463.
77. Nakano T., Lau G.M., Sugiyama M., Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32(2):339-345.
78. Neddermann P., Quintavalle M., Di Pietro C., Clementi A., Cerretani M., Altamura S., Bartholomew L., De Francesco R. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. Journal of Virology 2004, 78(23):13306-13314.
79. Nettles R.E., Gao M., Bifano M., Chung E., Persson A., Marbury T.C., Goldwater R., DeMicco M.P., Rodriguez-Torres M., Vutikullird A., Fuentes E., Lawitz E., Lopez-Talavera J.C., Grasela D.M. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54(6):1956-1965.
80. O'Boyle D.R., Nower P.T., Lemm J.A., Valera L., Sun J.H., Rigat K., Colonno R., Gao M. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrobial Agents and Chemotherapy 2005, 49(4):1346-1353.
81. Okamoto T., Nishimura Y., Ichimura T., Suzuki K., Miyamura T., Suzuki T., Moriishi K., Matsuura Y. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. The EMBO Journal 2006, 25(20):5015-5025.
82. Pasquinelli C., McPhee F., Eley T., Villegas C., Sandy K., Sheridan P., Persson A., Huang S.P., Hernandez D., Sheaffer A.K., Scola P., Marbury T., Lawitz E., Goldwater R., Rodriguez-Torres M., Demicco M., Wright D., Charlton M., Kraft W.K., Lopez-Talavera J.C., Grasela D.M. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents and Chemotherapy 2012, 56(4):1838-1844.
83. Pawlotsky J.M. New antiviral agents for hepatitis C. F1000 Biology Reports 2012, 4:5.
84. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet Infectious Diseases 2012, 12:717-728.
85. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39(1):5-19.
86. Plaza Z., Soriano V., Vispo E., Del Mar Gonzalez M., Barreiro P., Seclen E., Poveda E. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antiviral Therapy 2012, 17:921-926.
87. Pol S., Ghalib R.H., Rustgi V.K., Martorell C., Everson G.T., Tatum H.A., Hezode C., Lim J.K., Bronowicki J.P., Abrams G.A., Brau N., Morris D.W., Thuluvath P.J., Reindollar R.W., Yin P.D., Diva U., Hindes R., McPhee F., Hernandez D., Wind-Rotolo M., Hughes E.A., Schnittman S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. The Lancet Infectious Diseases 2012, 12:671-677.
88. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364(13):1195-1206.
89. Qiu D., Lemm J.A., O'Boyle D.R., 2nd, Sun J.H., Nower P.T., Nguyen V., Hamann L.G., Snyder L.B., Deon D.H., Ruediger E., Meanwell N.A., Belema M., Gao M., Fridell R.A. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. The Journal of General Virology 2011, 92(Pt 11):2502-2511.
90. Quinkert D., Bartenschlager R., Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. Journal of Virology 2005, 79(21):13594-13605.
91. Quintavalle M., Sambucini S., Di Pietro C., De Francesco R., Neddermann P. The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. Journal of Virology 2006, 80(22):11305-11312.
92. Ratziu V., Gadano A., Pol S., Hézode C., Ramji A., Cheng W., Sulkowsk M., Everson G., Diva U., McPhee F., Wind-Rotolo M., Hughes E.A., Yin P.D., Schnittman S. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of Phase 2b COMMAND-2 trial. Journal of Hepatology 2012, 56:S478-S479.
93. Romine, J.L., Martin, S.W., Snyder, L.B., Serrano-Wu, M., Deshpande, M., Whitehouse, D., Lemm, J., O'Boyle, D., Gao, M., Colonno, R., 2007. Iminothiazolidinones as inhibitors of HCV replication, U.S. patent 7,183,302 B2.
94. Romine J.L., St Laurent D.R., Leet J.E., Martin S.W., Serrano-Wu M.H., Yang F., Gao M., O'Boyle D.R., Lemm J.A., Sun J.-H., Nower P.T., Huang X., Deshpande M.S., Meanwell N.A., Snyder L.B. Inhibitors of HCV NS5A: from Iminothiazolidinones to Symmetrical Stilbenes. ACS Medicinal Chemistry Letters 2011, 2(3):224-229.
95. Rong L., Dahari H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Science Translative Medicine 2010, 2(30):30ra32.
96. Schijman A., Colina R., Mukomolov S., Kalinina O., Garcia L., Broor S., Bhupatiraju A.V., Karayiannis P., Khan B., Mogdasy C., Cristina J. Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes. Clinical and Diagnostic Laboratory Immunology 2004, 11(2):433-435.
97. Shi S.T., Polyak S.J., Tu H., Taylor D.R., Gretch D.R., Lai M.M. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002, 292(2):198-210.
98. Shimakami T., Hijikata M., Luo H., Ma Y.Y., Kaneko S., Shimotohno K., Murakami S. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. Journal of Virology 2004, 78(6):2738-2748.
99. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42(4):962-973.
100. Simmonds P., Holmes E.C., Cha T.A., Chan S.W., McOmish F., Irvine B., Beall E., Yap P.L., Kolberg J., Urdea M.S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. The Journal of General Virology 1993, 74(Pt 11):2391-2399.
101. Soriano V., Gane E., Angus P., Stickel F., Bronowicki J.P., Roberts S., Manns M., Zeuzem S., Dai L., Boecher W., Stern J., Mensa F. The efficacy and safety of the interferon-free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis - interim analysis from SOUND-C2. Journal of Hepatology 2012, 56:S559.
102. Stone M., Jia S., Heo W.D., Meyer T., Konan K.V. Participation of rab5, an early endosome protein, in hepatitis C virus RNA replication machinery. Journal of Virology 2007, 81(9):4551-4563.
103. Sulkowski M., Gardiner D., Lawitz E., Hinestrosa F., Nelson D., Thuluvath P., Rodriguez-Torres M., Lok A., Schwartz H., Reddy K.R., Eley T., Wind-Rotolo M., Huang S.P., Gao M., McPhee F., Hindes R., Symonds B., Pasquinelli C., Grasela D. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. Journal of Hepatology 2012, 56:S560.
104. Sulkowski M., Rodriguez-Torres M., Lawitz E., Shiffman M., Pol S., Herring R., McHutchison J., Pang P., Brainard D., Wyles D., Habersetzer F. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: Interim results. Journal of Hepatology 2012, 56:S560.
105. Sullivan G.J., Rodriques-Torres M., Lawitz E., Poordad F., Kapoor M., Campbell A., Setze C., Xie W., Khatri A., Dumas E., Krishnan P., Pilot-Matias T., Williams L., Bernstein B. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. Journal of Hepatology 2012, 56:S480.
106. Suzuki F., Ikeda K., Toyota J., Karino Y., Ohmura T., Chayama K., Takahashi S., Kawakami Y., Ishikawa H., Watanabe H., Hu W., McPhee F., Hughes E., Kumada H. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. Journal of Hepatology 2012, 56:S7-S8.
107. Suzuki F., Sezaki H., Akuta N., Suzuki Y., Seko Y., Kawamura Y., Hosaka T., Kobayashi M., Saito S., Arase Y., Ikeda K., Mineta R., Watahiki S., Miyakawa Y., Kumada H. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 2012, 54(4):352-354.
108. Tan S.L., Pause A., Shi Y., Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nature reviews. Drug Discovery 2002, 1(11):867-881.
109. Tanji Y., Kaneko T., Satoh S., Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. Journal of Virology 1995, 69(7):3980-3986.
110. Targett-Adams P., Boulant S., McLauchlan J. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. Journal of Virology 2008, 82(5):2182-2195.
111. Targett-Adams P., Graham E.J., Middleton J., Palmer A., Shaw S.M., Lavender H., Brain P., Tran T.D., Jones L.H., Wakenhut F., Stammen B., Pryde D., Pickford C., Westby M. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. Journal of Virology 2011, 85(13):6353-6368.
112. Tellinghuisen T.L., Foss K.L., Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathogens 2008, 4(3):e1000032.
113. Tellinghuisen T.L., Foss K.L., Treadaway J.C., Rice C.M. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. Journal of Virology 2008, 82(3):1073-1083.
114. Tellinghuisen T.L., Marcotrigiano J., Gorbalenya A.E., Rice C.M. The NS5A protein of hepatitis C virus is a zinc metalloprotein. The Journal of Biological Chemistry 2004, 279(47):48576-48587.
115. Tellinghuisen T.L., Marcotrigiano J., Rice C.M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005, 435(7040):374-379.
116. The Global Burden of Hepatitis C Working Group Global burden of disease (GBD) for hepatitis C. Journal of Clinical Pharmacology 2004, 44(1):20-29.
117. Toyoda H., Fukuda Y., Hayakawa T., Takayama T., Kumada T., Nakano S., Takamatsu J., Saito H. Characteristics of patients with chronic infection due to hepatitis C virus of mixed subtype: prevalence, viral RNA concentrations, and response to interferon therapy. Clinical Infectious Diseases 1998, 26(2):440-445.
118. Waller H., Chatterji U., Gallay P., Parkinson T., Targett-Adams P. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A. Journal of Virological Methods 2010, 165(2):202-210.
119. Wang C., Gale M., Keller B.C., Huang H., Brown M.S., Goldstein J.L., Ye J. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Molecular Cell 2005, 18(4):425-434.
120. Vince B., Lawitz E., Searle S., Marbury T., Robison H., Robarge L., Olek E. Novel NS5A inhibitor ACH-2928 Phase I results in HCV GT-1 patients. Journal of Hepatology 2012, 56:S480-S481.
121. Wolk B., Sansonno D., Krausslich H.G., Dammacco F., Rice C.M., Blum H.E., Moradpour D. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. Journal of Virology 2000, 74(5):2293-2304.
122. Wong K.A., Worth A., Brainard D.M., Lawitz E., Miller M.D., Mo H. Persistence of NS5A GS-5885 drug resistance mutations following 3 days of monotherapy in genotype-1 HCV patients is dependent on the HCV subtype and specific mutation. Journal of Hepatology 2012, 56:S482.
123. Yang G., Wiles J., Patel D., Zhao Y., Fabrycki J., Weinheimer S., Marlor C., Rivera J., Wang Q., Gadhachanda V., Hashimoto A., Chen D., Pais G., Wang X., Deshpande M., Stauber K., Huang M., Phadke A. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors. Journal of Hepatology 2012, 56:S330.
124. Yu G.Y., Lee K.J., Gao L., Lai M.M. Palmitoylation and polymerization of hepatitis C virus NS4B protein. Journal of Virology 2006, 80(12):6013-6023.
125. Zeuzem S., Buggisch P., Agarwal K., Marcellin P., Sereni D., Klinker H., Moreno C., Zarski J.P., Horsmans Y., Mo H., Arterburn S., Knox S., Oldach D., McHutchison J.G., Manns M.P., Foster G.R. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012, 55(3):749-758.